Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D - Top-Institutions - MDSpire

Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D

A Q&A with iXCells Biotechnologies CEO, Steve Smith

  • February 25, 2026

  • 9 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Broad Institute of MIT and Harvard
    Broad Institute of MIT and Harvard

    Cambridge, MA

    Key Differentiators

    • Stem Cell Biology
    • Rare Disease Genomics
    • Translational Medicine

  • #2

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Stem Cell Research
    • Neurodegenerative Diseases
    • Rare Disease Modeling

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Stem Cell and Regenerative Medicine
    • Rare Genetic Disorders
    • Precision Medicine

  • #4

    Harvard Stem Cell Institute (HSCI)
    Harvard Stem Cell Institute (HSCI)

    Cambridge, MA

    Key Differentiators

    • Stem Cell Biology
    • Rare Disease Modeling
    • Drug Discovery

  • #5

    The Jackson Laboratory
    The Jackson Laboratory

    Bar Harbor, ME

    Key Differentiators

    • Genetics
    • Stem Cell Models
    • Rare Disease Research

Original Source(s)

Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D

  • February 25, 2026

Related Content

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy